Prima Biomed Ltd. (PBMD)
-NasdaqGM 2.40 0.00(0.00%) 10:23AM EDT - Nasdaq Real Time Price
| Prev Close: | 2.40 |
|---|
| Open: | 2.40 |
|---|
| Bid: | 2.40 x 100 |
|---|
| Ask: | 2.59 x 400 |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 2.692 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2.40 - 2.40 |
|---|
| 52wk Range: | 1.70 - 7.49 |
|---|
| Volume: | 2,150 |
|---|
| Avg Vol (3m): | 2,992 |
|---|
| Market Cap: | 85.28M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.54 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Prima BioMed to Present at the Second Annual Marcum LLP MicroCap ConferenceMarketwired(Mon, May 20)
- Prima BioMed Issues the Following Notice to Stockholders of the CompanyMarketwired(Thu, May 16)
- Russell J. Howard to Join Prima BioMed's Board of DirectorsMarketwired(Tue, May 7)
- Prima Biomed's CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, Apr 23)
- Prima BioMed Updates Clinical Leadership TeamMarketwired(Tue, Apr 23)
- Prima Biomed Quarterly Results and Conference CallMarketwired(Fri, Apr 19)
- Prima BioMed awarded Japanese patent for CVactheflyonthewall.com(Wed, Apr 17)
- Prima BioMed Awarded Japanese Patent for CVac(TM)Marketwired(Wed, Apr 17)
- 3.8 Million Euro Grant to Support CVAC(TM) Development; Prima Moving Forward With Pilot Trials of CVAC in Additional Cancer IndicationsMarketwired(Tue, Mar 19)
- Prima BioMed to Present at ISBioTech Annual MeetingMarketwired(Sun, Mar 10)
- Prima BioMed Conference Call to Discuss First Half of Fiscal Year 2013 ResultsMarketwired(Mon, Mar 4)
- Prima Biomed Commences "CANVAS" Clinical Trial in EuropeMarketwired(Wed, Feb 27)
- Prima BioMed Announces Two Accepted Abstracts for Presentation at ISCT Annual MeetingMarketwired(Sun, Feb 3)
- Prima BioMed To Get Key Data In Second Halfat Seeking Alpha(Wed, Jan 30)
- Prima BioMed to Present at the 15th Annual BIO CEO & Investor ConferenceMarketwired(Mon, Jan 28)
Reports
- No Reports available for PBMD at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 54.81 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Prima BioMed Ltd, a biotechnology company, engages in the research and commercialization of licensed medical biotechnology products in Australia. It develops oncology therapies in the field of immunotherapy.
View More 
0.44%